Loading
A PET scan using a radioactive hormone mimic that lights up neuroendocrine tumours and shows whether the matching radioactive treatment will work.
68Ga-DOTATATE (Netspot, 2016), 68Ga-DOTATOC (2019) and 64Cu-DOTATATE (Detectnet, 2020) replaced 111In-octreotide scintigraphy, with far higher sensitivity for small lesions and bone disease. Mandatory for staging, for selecting patients for PRRT (Krenning score ≥3 or uptake above liver), and for detecting occult primaries. FDG PET complements it in high-grade or dedifferentiated disease ('flip-flop' pattern).
Radiolabelled somatostatin analogue binds SSTR2 on tumour cells; positron emission imaged by PET/CT.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
Query for this technology: (TITLE:"Somatostatin receptor PET" OR ABSTRACT:"Somatostatin receptor PET" OR TITLE:"68Ga/64Cu-DOTATATE" OR ABSTRACT:"68Ga/64Cu-DOTATATE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Somatostatin receptor PET (68Ga/64Cu-DOTATATE), not a curated reading list.
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Grade 3 well-differentiated neuroendocrine tumour, Theranostics, Peptide receptor radionuclide therapy (PRRT).
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Advanced Accelerator Applications (Novartis), Lutetium-177 dotatate.
Shares SSTR PET → PRRT, Grade 3 well-differentiated neuroendocrine tumour, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2.
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Theranostics, Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
Shares Grade 3 well-differentiated neuroendocrine tumour, Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Extrapulmonary neuroendocrine carcinoma, Small intestinal neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Lutetium-177 dotatate, Small intestinal neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.